Grifols SA reported strong financial results for 2023, with total revenue of EUR 6,592 million (up 10.9%), and an adjusted EBITDA of EUR 1,474 million (26% increase), alongside a net profit of EUR 59 million including restructuring costs. The company's leverage ratio improved to 6.3x, and it anticipates revenue growth of over 7% in 2024 driven by Biopharma operations.